Epigenetic alterations and anti-epigenetic therapy in myelofibrosis

Leukemia and Lymphoma

Volumn 49, Issue 12, 2008, Pages 2231-2232

  Tefferi, Ayalew ^a  

^a MAYO CLINIC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

5 AZA 2' DEOXYCYTIDINE; AZACITIDINE; CD34 ANTIGEN; DEPSIPEPTIDE; HISTONE DEACETYLASE; HISTONE DEACETYLASE INHIBITOR; ITF 2357; PANOBINOSTAT; TRICHOSTATIN A; UNCLASSIFIED DRUG; VALPROIC ACID; VORINOSTAT;

CLINICAL TRIAL; CPG ISLAND; DNA METHYLATION; EPIGENETICS; GENE MUTATION; HUMAN; MYELOFIBROSIS; MYELOID METAPLASIA; NOTE; PHENOTYPIC VARIATION; POLYCYTHEMIA VERA; PRIORITY JOURNAL; PROMOTER REGION; THROMBOCYTHEMIA;

ANTINEOPLASTIC AGENTS; DRUG DELIVERY SYSTEMS; EPIGENESIS, GENETIC; HUMANS; PRIMARY MYELOFIBROSIS;

EID: 57449089334     PISSN: 10428194     EISSN: 10292403     Source Type: Journal    
DOI: 10.1080/10428190802578866     Document Type: Note

References (21)

1. Stindl, R. (2008) Defining the steps that lead to cancer: Replicative telomere erosion, aneuploidy and an epigenetic maturation arrest of tissue stem cells. Med Hypotheses, 71, pp. 126-140.
2. Tefferi, A. and Vardiman, J. W. (2008) Classification and diagnosis of myeloproliferative neoplasms: The 2008 World Health Organization criteria and point-of-care diagnostic algorithms. Leukemia, 22, pp. 14-22.
3. Tefferi, A. and Gilliland, D. G. (2007) Oncogenes in myeloproliferative disorders. Cell Cycle, 6, pp. 550-566.
4. Druker, B. J., Guilhot, F., O'Brien, S. G., Gathmann, I., Kantarjian, H. Gattermann, N. et al. (2006) Five-year follow-up of patients receiving imatinib for chronic myeloid leukemia. N Engl J Med, 355, pp. 2408-2417.
5. Pardanani, A., Brockman, S. R., Paternoster, S. F., Flynn, H. C., Ketterling, R. P. Lasho, T. L. et al. (2004) FIP1L1-PDGFRA fusion: prevalence and clinicopathologic correlates in 89 consecutive patients with moderate to severe eosinophilia. Blood, 104, pp. 3038-3045.
6. Tefferi, A. (2008) JAK and MPL mutations in myeloid malignancies. Leuk Lymphoma, 49, pp. 388-397.
7. Tefferi, A. (2008) Essential thrombocythemia, polycythemia vera, and myelofibrosis: Current management and the prospect of targeted therapy. Am J Hematol, 83, pp. 491-497.
8. Pardanani, A. (2008) JAK2 inhibitor therapy in myeloproliferative disorders: Rationale, preclinical studies and ongoing clinical trials. Leukemia, 22, pp. 23-30.
9. Silverman, L. R., Demakos, E. P., Peterson, B. L., Kornblith, A. B., Holland, J. C. Odchimar-Reissig, R. et al. (2002) Randomized controlled trial of azacitidine in patients with the myelodysplastic syndrome: A study of the cancer and leukemia group B. J Clin Oncol, 20, pp. 2429-2440.
10. Kantarjian, H., Issa, J. P., Rosenfeld, C. S., Bennett, J. M., Albitar, M. Dipersio, J. et al. (2006) Decitabine improves patient outcomes in myelodysplastic syndromes: Results of a phase III randomized study. Cancer, 106, pp. 1794-1803.
11. Ihalainen, J., Juvonen, E., Savolainen, E. R., Ruutu, T. and Palotie, A. (1994) Calcitonin gene methylation in chronic myeloproliferative disorders. Leukemia, 8, pp. 230-235.
12. Wang, J. C., Chen, W., Nallusamy, S., Chen, C. and Novetsky, A. D. (2002) Hypermethylation of the P15INK4b and P16INK4a in agnogenic myeloid metaplasia (AMM) and AMM in leukaemic transformation. Br J Haematol, 116, pp. 582-586.
13. Kumagai, T., Tefferi, A., Jones, L. and Koeffler, H. P. (2005) Methylation analysis of the cell cycle control genes in myelofibrosis with myeloid metaplasia. Leuk Res, 29, pp. 511-515.
14. Jones, L. C., Tefferi, A., Idos, G. E., Kumagai, T., Hofmann, W. K. and Koeffler, H. P. (2004) RARbeta2 is a candidate tumor suppressor gene in myelofibrosis with myeloid metaplasia. Oncogene, 23, pp. 7846-7853.
15. Bogani, C., Ponziani, V., Guglielmelli, P., Desterke, C., Rosti, V. Bosi, A. et al. (2008) Hypermethylation of CXCR4 promoter in CD34+ cells from patients with primary myelofibrosis. Stem Cells, 26, pp. 1920-1930.
16. Fourouclas, N., J, Li, Gilby, D. C., Campbell, P. J., Beer, P. A. Boyd, E. M. et al. (2008) Methylation of the suppressor of cytokine signaling 3 gene (SOCS3) in myeloproliferative disorders. Haematologica, 93, pp. 1635-1644.
17. Wang, J. C., Chen, C., Dumlao, T., Naik, S., Chang, T. Xiao, Y. -Y. et al. (2008) Enhanced histone deacytlase enzyme activity in primary myelofibrosis. Leuk Lymphoma, 49, pp. 2321-2327.
18. Shi, J., Zhao, Y., Ishii, T., Hu, W., Sozer, S. Zhang, W. et al. (2007) Effects of chromatin-modifying agents on CD34+ cells from patients with idiopathic myelofibrosis. Cancer Res, 67, pp. 6417-6424.
19. Guerini, V., Barbui, V., Spinelli, O., Salvi, A., Dellacasa, C. Carobbio, A. et al. (2008) The histone deacetylase inhibitor ITF2357 selectively targets cells bearing mutated JAK2(V617F). Leukemia, 22, pp. 740-747.
20. Quintas-Cardama, A., Tong, W., Kantarjian, H., Thomas, D., Ravandi, F. Kornblau, S. et al. (2008) A phase II study of 5-azacitidine for patients with primary and post-essential thrombocythemia/polycythemia vera myelofibrosis. Leukemia, 22, pp. 965-970.
21. Mesa, R. A., Verstovsek, S., Rivera, C., Pardanani, A., Hussein, K. Lasho, T. et al. 5-Azacitidine has limited therapeutic activity in myelofibrosis. Leukemia